Background
The potential role of multimedia
Methods
Development of the multimedia intervention
Methods of the SWAT
Outcome measures
Ethical approval
Data analysis
Results
Trial name | Population | Host trial intervention and comparison | Design of the host trial | Design of SWAT |
---|---|---|---|---|
GHT2000 [21] | Inactive 18–74-year-olds with hypertension, suspected hypertension, pre-hypertension or high-normal blood pressure | Interventions: (i) GP gym-based referral plus web tool, (ii) sport referral (iii) sport referral plus web tool Comparator: GP gym-based referral | Individually randomised four-arm group trial | Two-arm trial, individually randomised |
PSM COPD [22] | COPD patients aged 18 years or older with mild dyspnoea | Intervention: a telephone-based self-management intervention Comparator: usual care | Individually randomised two-arm group trial | Two-arm trial, clustered by general practice |
HI-Light [23] | Patients aged 5 years and over with vitiligo | Interventions: (i) Handheld narrowband UVB (NB-UVB) and (ii) a combination of potent topical corticosteroid and NB-UVB, compared with potent topical corticosteroid | Individually randomised three-arm, placebo-controlled | Two-arm trial, individually randomised |
seAFOod [24] | Patients aged 55–73 years identified during screening colonoscopy as being at ‘high risk’ for subsequent surveillance colonoscopy | Interventions: (i) 2 g eicosapentaenoic acid per day and (ii) 300 mg aspirin per day Comparator: placebo | Individually randomised 2 by 2 factorial trial | Two-arm trial, cluster randomised ( Endoscopy Unit taking part in the UK NHS Bowel Cancer Screening Programme) |
STOP ACEi [20] | Patients with advanced progressive CKD receiving angiotensin-converting enzyme inhibitor or angiotensin receptor blockers (or both) | Intervention: Discontinue Angiotensin Converting enzyme inhibitor (ACEi)/Angiotensin Receptor Blocker (ARB) or combination of both Comparator: Continue ACEi, ARB or combination of both | Individually randomised two-arm group trial | Two-arm trial, individually randomised |
Study | Standard | Multimedia | Odds ratio (95% CI) | % weight |
---|---|---|---|---|
GHT2000 | 64/1049 (5.9%) | 57/1048 (5.4%) | 0.89 (0.61 to 1.28) | 27.7 |
GHT2000 (reminder) | 41/1057 (3.9%) | 35/1055 (3.3%) | 0.85 (0.54 to 1.35) | 18.2 |
PSM COPD | 247/2280 (10.8%) | 185/1934 (9.6%) | 0.84 (0.58 to 1.22) | 28.2 |
HI-Light | 51/1136 (4.5%) | 54/1094 (4.9%) | 1.11 (0.60 to 2.02) | 10.4 |
seAFOod | 61/395 (15.4%) | 68/333 (20.4%) | 1.44 (0.88 to 2.37) | 15.5 |
Pooled | 464/5917 (7.8%) | 399/5464 (7.3%) | 0.96 (0.79 to 1.17) | 100.0 |
Study | Standard | Multimedia | Odds ratio (95% CI) | % weight |
---|---|---|---|---|
GHT2000 | 100/1049 (9.5%) | 87/1048 (8.3%) | 0.86 (0.64 to 1.16) | 23.8 |
GHT2000 (reminder) | 59/1057 (5.6%) | 53/1055 (5.0%) | 0.90 (0.61 to 1.31) | 14.4 |
PSM COPD | 464/2280 (20.3%) | 412/1934 (21.3%) | 1.02 (0.79 to 1.33) | 30.3 |
HI-Light | 221/1136 (19.5%) | 226/1094 (20.7%) | 1.08 (0.83 to 1.40) | 31.6 |
Pooled | 844/5522 (15.3%) | 778/5131 (15.2%) | 0.98 (0.85 to 1.13) | 100.0 |
Study | Standard | Multimedia | Odds ratio (95% CI) | % weight |
---|---|---|---|---|
PSM COPD (at 12 months) | 223/2280 (9.8%) | 159/1934 (8.2%) | 0.80 (0.54 to 1.18) | 44.8 |
HI-Light (at 9 months) | 35/1136 (3.1%) | 40/1094 (3.7%) | 1.19 (0.58 to 2.46) | 22.7 |
seAFOod (at 12 months) | 49/395 (12.4%) | 57/333 (17.1%) | 1.50 (0.87 to 2.6) | 32.5 |
Pooled | 307/3811 (8.1%) | 256/3361 (7.6%) | 1.07 (0.71 to 1.62) |